ProShare Advisors
NEOS

ProShare Advisors’s Neos Therapeutics, Inc NEOS Stock Holding History

ProShare Advisors’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,568
Closed -$76K – 1764
2018
Q3 		$76K Sell
15,568
-265
-2% -$1.5K ﹤0.01% 1701
2018
Q2 		$99K Sell
15,833
-738
-4% -$5.5K ﹤0.01% 1710
2018
Q1 		$138K Sell
16,571
-2,724
-14% -$26K ﹤0.01% 1600
2017
Q4 		$197K Buy
+19,295
New +$185K ﹤0.01% 1647
2016
Q4 		– Sell
-11,490
Closed -$76K – 1763
2016
Q3 		$76K Sell
11,490
-2,132
-16% -$16.9K ﹤0.01% 1428
2016
Q2 		$126K Buy
13,622
+1,233
+10% +$11.8K ﹤0.01% 1497
2016
Q1 		$134K Sell
12,389
-1,234
-9% -$13K ﹤0.01% 1489
2015
Q4 		$195K Buy
+13,623
New +$205K ﹤0.01% 1551

Other funds holding NEOS

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's NEOS Position: Q4 2018 in Review

ProShare Advisors sold out of Neos Therapeutics, Inc (NEOS) in Q4 2018, closing a stake of 15,568 shares — an estimated $76K sold.

ProShare Advisors first reported a position in NEOS in Q4 2015 and held it in 8 quarters. The position peaked at $197K in Q4 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q4 2018.

  • ProShare Advisors reported no remaining Neos Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • ProShare Advisors sold 15,568 Neos Therapeutics, Inc shares in Q4 2018, an estimated $76K.
  • ProShare Advisors first reported a position in Neos Therapeutics, Inc in Q4 2015 and held it in 8 quarters.
  • ProShare Advisors's Neos Therapeutics, Inc position peaked at $197K in Q4 2017.
  • 63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q4 2018.

Based on ProShare Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.